Weight-loss surgery for fatty liver disease with scarring in people with obesity
Follows people with obesity having weight-loss surgery to see effects on fatty liver disease.
Plain-language title generated from the registry record
Registry title: Effectiveness of Bariatric Surgery for NAFLD/NASH
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for obese adults and teenagers who are scheduled for their first weight-loss (bariatric) surgery and who have fatty liver disease.
- Age
- 16 to 65 years.
- Sex
- All sexes can join.
- Disease stage
- Obesity (by the World Health Organization criteria for Asian populations) with fatty liver found on imaging or on a liver tissue test. For the second group (Base-NASH): NASH with fibrosis confirmed on a liver tissue test, with NAFLD activity score of 4 or more and fibrosis stage F1 or higher.
- Earlier treatment
- Must be scheduled for a first weight-loss surgery. People who already had any type of bariatric surgery cannot join.
Main reasons for not taking part
- Earlier bariatric surgery of any type
- Heavy drinking in the past 12 months (men more than 30g a day, women more than 20g a day)
- Taking amiodarone, methotrexate, tamoxifen or glucocorticoids
- Other causes of fatty liver, such as genotype 3 hepatitis C, autoimmune hepatitis or celiac disease
- Cancer (diagnosed or suspected) or earlier major stomach or bowel surgery
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 65 years old?
Source: NCT04366999, who can take part
Where in China
- Beijing Friendship HospitalBeijing, ChinaContact: Zhongtao Zhang, M.D.;Ph.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Friendship Hospital
- Trial code
- NCT04366999
- Record updated
- 14 May 2024
- Original description
This is a prospective, multicenter cohort study, which subjects were obese patients requiring bariatric surgery.Read full original descriptionShow less
Effectiveness of Bariatric Surgery for Nonalcoholic Fatty Liver Diseases/Nonalcoholic Steatohepatitis With Fibrosis : A Prospective, Multicentric Cohort Study
This is a prospective, multicenter cohort study, which subjects were obese patients requiring bariatric surgery.
This study aims to explore the the effectiveness of bariatric surgery for NAFLD/NASH with fribrosis, to explore the differences in the effectiveness among sleeve gastrostomy [SG], Roux-en-Y gastric bypass [RYGB], or one anastomosis gastric bypass [OAGB], and to explore the independent effectiveness of bariatric surgery in histological remission of NAFLD/NASH.
The first stage of the cohort was started in 2020, named Base-NAFLD; In May 2024, based on Base-NAFLD, we plan to continue established a secondary cohort, named Base-NASH.
Inclusion: [For Base-NAFLD]; Age between 16 and 65 years (all sexes); Diagnosed with obesity according to the World Health Organization criteria for obesity in Asian populations and scheduled for a primary bariatric surgery at the participating centres; Diagnosed with hepatic steatosis preoperatively by radiologic (including ultrasonography, magnetic resonance imaging [MRI]-derived proton density fat fraction [PDFF]) or pathologic(intraoperative hepatic pathology) examinations; [For Base-NASH]; Age between 16 and 65 years (all sexes); Diagnosed with obesity according to the World Health Organization criteria for obesity in Asian populations and scheduled for a primary bariatric surgery at the participating centres; Histologically confirmed NASH with fibrosis:; NAFLD activity score(NAS) ≥4 with at least 1 in each single item and NASH-CRN fibrosis stage ≥F1.
Exclusion: any patient who had previously been submitted to any type of bariatric surgery; previous major gastrointestinal surgery；; history of excessive drinking: in the past 12 months, the male equivalent of alcohol consumption more than 30g/d, and the female more than 20g/d; history of taking amiodarone, methotrexate, tamoxifen, glucocorticoids, etc.；; history of specific diseases: Gene type 3 hepatitis C virus (HCV) infection, hepatolenticular degeneration, autoimmune hepatitis, total parenteral nutrition, lack of beta lipoproteinemia, congenital lipid atrophy, celiac disease which causing fatty liver, etc; diagnosed or suspected malignancy；; poorly controlled significant medical or psychiatric disorders；; disorders such as a medical history of major pathology; can not be able to understand and willing to participate in this registry with signature.